Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Department of Medicine, Vanderbilt University Medical Center, Nashville, TN.
JCO Clin Cancer Inform. 2023 Aug;7:e2300082. doi: 10.1200/CCI.23.00082.
Altmetric Attention Scores (Altmetrics) are real-time measures of scientific impact and attention through various public outlets, including news, blogs, and social media. Herein, we aimed to describe and characterize the relationship between Altmetrics, conventional impact metrics, and features of published cancer clinical trials.
We identified two-arm phase III cancer randomized clinical trials with a superiority end point and publication date between 2015 and 2020 from HemOnc and tabulated the following data: Altmetric, study positivity, US Food and Drug Administration (FDA) registration trial status, cancer site/category, treatment context (curative or palliative), trial design, primary end point type, experimental/control arm modality, and journal tier. We further collected conventional bibliometrics including the number of citations and relative citation ratio (RCR) for all published studies. Multiple linear regression modeling identified clinical trial factors predictive of Altmetrics, with alpha = .05 defining statistical significance.
Altmetrics were found for 681 (98%) of 698 publications, with a median score of 38.5 (IQR, 13-132.8). FDA registration studies (β [95% CI], 84.7 [48.8 to 120.6]; < .001), studies reporting on curative (as opposed to palliative) interventions (-29 [-53.7 to -4.4]; = .02), genitourinary trials (73.2 [28.1 to 118.2]; = .001), studies published in tier 1 journals ( < .001), and those with an increased number of citations per year (0.81 [0.66 to 0.95]; < .001) were significantly associated with increased engagement as measured by Altmetrics. Furthermore, there was a strong correlation between all collected bibliometrics and Altmetrics ( = 0.63, 0.68, and 0.67; < .001 for citation count, citations per year, and RCR, respectively).
FDA registration trials describing curative interventions, studies published in traditionally defined high-impact journals, and genitourinary trial publications tend to have the greatest Altmetrics. We observed a strong relationship between Altmetrics and conventional bibliometrics. The significance and consequences of these relationships warrant further investigation.
Altmetric 关注度得分（Altmetrics）是通过各种公共渠道（包括新闻、博客和社交媒体）实时衡量科学影响力和关注度的指标。本研究旨在描述和分析 Altmetrics 与传统影响力指标以及已发表癌症临床试验特征之间的关系。
我们从 HemOnc 数据库中确定了 2015 年至 2020 年间发表的具有优效性终点的两项随机 III 期癌症临床试验，并列出以下数据：Altmetrics、研究阳性结果、美国食品和药物管理局（FDA）注册试验状态、癌症部位/类别、治疗背景（根治性或姑息性）、试验设计、主要终点类型、实验组/对照组模式和期刊等级。我们还收集了所有已发表研究的传统文献计量学指标，包括引用数量和相对引用率（RCR）。采用多元线性回归模型确定与 Altmetrics 相关的临床试验因素，α 值为.05 表示具有统计学意义。
共发现 698 篇出版物中的 681 篇（98%）有 Altmetrics，中位数为 38.5（IQR，13-132.8）。FDA 注册研究（β [95%CI]，84.7 [48.8 至 120.6]； <.001）、报告根治性（而非姑息性）干预措施的研究（-29 [-53.7 至-4.4]； =.02）、泌尿生殖系统试验（73.2 [28.1 至 118.2]； =.001）、发表于 1 级期刊的研究（ <.001）以及每年引文数量增加的研究（0.81 [0.66 至 0.95]； <.001）与 Altmetrics 衡量的关注度增加显著相关。此外，所有收集到的文献计量学指标与 Altmetrics 之间均存在较强的相关性（ = 0.63、0.68 和 0.67；分别对应于引文数量、每年引文数量和 RCR， <.001）。
描述根治性干预措施的 FDA 注册试验、发表于传统高影响力期刊的研究以及泌尿生殖系统试验出版物往往具有最高的 Altmetrics。我们观察到 Altmetrics 与传统文献计量学指标之间存在很强的关系。这些关系的意义和后果值得进一步研究。
